2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.08F.12 Toxicity and Outcomes by Radio-Sensitizing Chemotherapy Regimen for Unresectable Stage III NSCLC in British Columbia, Canada

EP.08F.12 Toxicity and Outcomes by Radio-Sensitizing Chemotherapy Regimen for Unresectable Stage III NSCLC in British Columbia, Canada

Back to course

Pdf Summary

This study investigates the effects of different radio-sensitizing chemotherapy regimens on toxicity and patient outcomes in unresectable stage III non-small cell lung cancer (NSCLC) treated with concurrent chemoradiotherapy (CRT) followed by durvalumab consolidation. The standard of care involves either platinum and etoposide (PE) given every three weeks or weekly carboplatin-paclitaxel (CP) for sensitization during CRT. The study was conducted at BC Cancer, British Columbia, Canada, and spanned January 2018 to December 2020 with a retrospective review of 202 patients' charts.<br /><br />Key findings include:<br />- CP regimens were better tolerated, with a lower incidence of high-grade adverse events compared to PE regimens.<br />- Pneumonitis was recorded in 23% of the patients. The incidence of pneumonitis did not significantly differ between the PE and CP regimens, although pneumonitis negatively impacted treatment completion, with 60% of those affected unable to finish durvalumab consolidation.<br />- Despite its impact on treatment completion, pneumonitis did not significantly affect overall survival (OS) based on Kaplan-Meier analysis (p=0.256).<br />- There was no significant difference in median OS between patients receiving the PE versus CP regimens (p=0.157).<br /><br />Overall, the study suggests that while CP regimens offer a better tolerability profile with fewer high-grade adverse effects, both regimens show similar rates of pneumonitis which does not adversely impact overall survival. These findings could inform treatment decisions concerning CRT regimens and management for unresectable stage III NSCLC.

Asset Subtitle

Marie-Frédérique Damours

Meta Tag

Speaker Marie-Frédérique Damours

Topic Local-Regional Non-small Cell Lung Cancer

Keywords

radio-sensitizing chemotherapy

toxicity

patient outcomes

unresectable stage III NSCLC

concurrent chemoradiotherapy

durvalumab consolidation

platinum etoposide

carboplatin-paclitaxel

pneumonitis

overall survival